Ultrashape is involved in developing and manufacturing of non-invasive technologies for fat cell destruction and body sculpting.

Syneron said now Ultrashape’s products, which are approved in Europe, Canada, Latin America and Asia, will now be available through its worldwide network of direct and distributor sales channels.

Syneron Medical CEO Louis Scafuri said Ultrashape’s technology provides a differentiated, physician and patient friendly, non-invasive treatment for de-bulking and body sculpting of normal to overweight patients.

"We are very excited to welcome the Ultrashape team to Syneron and look forward to working with them to begin our US clinical trial and continue broadening global exposure for this important technology," Scafuri added.